Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

AIM WINNERS & LOSERS: Touchstone up on gas find, C4X on Sanofi deal

12th Apr 2021 11:28

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Touchstone Exploration Inc, up 17% at 107.00 pence, 12-month range 22.2p-178p. The oil and gas explorer says flowback testing of one of its wells in Trinidad & Tobago confirmed a liquids-rich natural gas discovery. President & Chief Executive Paul Baay notes that the test results "demonstrate the clear future production opportunities for the company."

----------

C4X Discovery PLC, up 12% at 44.85p, 12-month range 11.5p-54.5p. The drug development firm signs exclusive worldwide licensing agreement with Sanofi SA for C4XD's oral pre-clinical IL-17A inhibitor programme. C4XD will receive an upfront payment of EUR7 million and could receive up to a further EUR407 million in potential development, regulatory and commercialisation milestones, of which EUR11 million is in pre-clinical milestones, in addition to single-digit royalties. Sanofi shares were up 0.2% in Paris.

----------

Elixirr International PLC, up 11% at 479p, 12-month range 185p-480p. The London-based consultancy says it performed "exceptionally well" in 2020. Elixirr International says 2020 revenue rose by 24% to GBP30.3 million from GBP24.5 million and pretax profit was up to GBP5.8 million from GBP1.7 million. Says trading in first quarter has been strong with revenue increasing by more than 60%.

----------

AIM - LOSERS

----------

Concurrent Technologies PLC, down 8.9% at 95.70p, 12-month range 82p-126p. The embedded computer products manufacturer says some project delays could see revenue shifting to 2022. Pretax profit in 2020 fell 32% to GBP2.8 million from GBP4.1 million in 2019. Revenue, however, improved 8.8% to GBP21.1 million from GBP19.4 million. Looking ahead, Concurrent says it is taking a cautious approach to revenue growth in the coming year because of the continuing uncertainty caused by the Covid-19 outbreak and the delays seen to some programmes potentially moving revenue from 2021 to 2022.

----------

By Arvind Bhunjun; [email protected]

Copyright 2021 Alliance News Limited. All Rights Reserved.


Related Shares:

C4XD.LTouchstone ExplorationConcurrent TechnologiesElixirr International
FTSE 100 Latest
Value8,809.74
Change53.53